LAS VEGAS, NV--(Marketwired - Jun 25, 2015) - Cell MedX Corp. (
Cell MedX President and CEO, Mr. Frank McEnulty comments, "Today's announcement is a noteworthy step in our development pathway. We intend to work closely with TDM Financial in order to maximize the impact of their extensive network and IR management expertise so as to provide increased investor education and extend shareholder outreach through their compliant and quality coverage across a number of major financial news portals. We anticipate this will lead to a heightened understanding of our achievements, technology and goals, along with the steps required to achieve commercial success by building and informing a dedicated audience that could propel our strategic growth."
"We are excited to be working with a company that, if early indicators prove successful, may actually be on-track to develop an entirely new category of diabetic treatment," said TDM Financial President Daniel Minton. "We look forward to communicating the company's growth strategy to the investment community and to building a stable, long-term shareholder base."
About Cell MedX Corp (
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is engaged in reselling and marketing of technology and equipment to the worldwide wellness industry as well as providing continuing education to health care professionals. For more information go to: www.cellmedx.com and visit us on Facebook.
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance Technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Contact Information:
For further information about Cell MedX Corp.
Please visit the Company's website at http://www.cellmedx.com.
Or phone us at 1-844-238-2692